Jun 27, 2022
Javier Szwarcberg, CEO of Spruce Biosciences, is developing a compound to address the needs of patients with classic congenital adrenal hyperplasia, CAH, a rare disease first diagnosed at birth. Only recently have companies started to explore innovative therapies to improve the standard of care discovered in the early...
Developing Small Molecule Compound to Manage Rare Disease Classic Congenital Adrenal Hyperplasia with Javier Szwarcberg Spruce Biosciences TRANSCRIPT
Download PDFJun 27, 2022
Javier Szwarcberg, CEO of Spruce Biosciences, is developing a compound to address the needs of patients with classic congenital adrenal hyperplasia, CAH, a rare disease first diagnosed at birth. Only recently have companies started to explore innovative therapies to improve the standard of care discovered in the early...
Developing Autologous Cell Therapy For Diabetic Foot Ulcer and Other Complex Wounds with Richard Hague PolarityTE TRANSCRIPT
Download PDFJun 23, 2022
Richard Hague is the CEO and President of PolarityTE, creating a paste-like substance containing multicellular skin segments that can be spread on the patient's wound bed and engrafts into the wound. This stimulates healing from the inside out with wounds created by diabetic foot ulcer and venous leg ulcer.
Richard...
Jun 23, 2022
Richard Hague is the CEO and President of PolarityTE, creating a paste-like substance containing multicellular skin segments that can be spread on the patient's wound bed and engrafts into the wound. This stimulates healing from the inside out with wounds created by diabetic foot ulcer and venous leg ulcer.
Richard...
Jun 22, 2022
Greg Sturmer is the Co-Founder and CEO of Elysium Therapeutics and rethinking how to overcome the challenges of opioid abuse and addiction by reformulating the drug itself. Blending an understanding of chemistry and human behavior, Elysium questions why it takes 70 years for an opioid to lose half its potency and what...